University of California San Francisco

Publications

Publications

  1. Locoregional Considerations for Invasive Lobular Carcinoma.
    2025 | PubMed
  2. Impact of concurrent lobular carcinoma in situ on recurrence outcomes in patients with classic and pleomorphic invasive lobular carcinoma of the breast.
    2025 | PubMed
  3. Cryoablation Versus Breast-Conserving Surgery for Early-Stage, Low-Risk Breast Cancer ≤ 1.5 cm: A Cost-Effectiveness Analysis.
    2025 | PubMed
  4. FNA biopsy of breast specimens effectively harvests cells for patient-derived organoids modeling ductal carcinoma in situ.
    2025 | PubMed
  5. ASO Visual Abstract: Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.
    2025 | UCSF Research Profile
  6. Impact of Time to Surgery Post Neoadjuvant Chemotherapy on Breast Cancer Outcomes: A Retrospective Study of Patients Enrolled in the I-SPY 2 Clinical Trial.
    2025 | PubMed
  7. ASO Visual Abstract: Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
    2025 | UCSF Research Profile
  8. Invasive lobular carcinoma: Strategies and perspectives from the lobular breast cancer research group.
    2025 | PubMed
  9. ASO Author Reflections: Equity in the Surgical Management of the Axilla.
    2025 | PubMed
  10. ASO Visual Abstract: Accuracy of Breast MRI for Surgical Planning After Neoadjuvant Therapy for Patients with Invasive Lobular Carcinoma.
    2025 | UCSF Research Profile
  11. Impact of Neoadjuvant Chemotherapy on Surgical Outcomes and Conversion to Node-Negativity in Invasive Lobular Breast Cancer: Analysis of Molecularly High-Risk Tumors by Histologic Subtype on the I-SPY2 Clinical Trial.
    2025 | PubMed
  12. Disparities in the Surgical Management of the Axilla by Self-Identified Race in the Multicenter Neoadjuvant I-SPY2 Trial.
    2025 | PubMed
  13. Clinical challenges and proposed solutions for patients with invasive lobular breast cancer.
    2025 | PubMed
  14. ASO Author Reflections: Accuracy of MRI in Invasive Lobular Carcinoma after Neoadjuvant Therapy: Impact of Non-mass Enhancement.
    2025 | PubMed
  15. Accuracy of Breast MRI for Surgical Planning After Neoadjuvant Therapy for Patients with Invasive Lobular Carcinoma.
    2025 | PubMed
  16. Socioeconomic status impacts tumor biology, treatment, and outcomes in over 200,000 patients with invasive lobular carcinoma of the breast: an analysis of the National Cancer Database.
    2025 | PubMed
  17. Combined prognostic impact of initial clinical stage and residual cancer burden after neoadjuvant systemic therapy in triple-negative and HER2-positive breast cancer: an analysis of the I-SPY2 randomized clinical trial.
    2025 | PubMed
  18. ASO Author Reflections: Reassessing Positive Margins in Breast-Conserving Surgery: The Role of Histology and Oncoplastic Surgery.
    2025 | PubMed
  19. Breast cancer diagnosis, management, and outcomes in transgender, nonbinary, and gender-diverse individuals: A multicenter cohort.
    2025 | UCSF Research Profile
  20. Circulating tumor DNA (ctDNA) in patients with stage 2/3 HR+HER2-negative breast cancer (BC) treated with neoadjuvant endocrine therapy (NET) in the I-SPY2 endocrine optimization pilot (EOP) trial.
    2025 | UCSF Research Profile
  21. I-SPY2 endocrine optimization pilot (EOP): Neoadjuvant lasofoxifene (Laso) in molecularly selected patients with hormone receptor positive (HR+)/HER2 negative (HER2-) stage 2/3 breast cancer (BC).
    2025 | UCSF Research Profile
  22. Patient experiences of diagnosis and treatment of invasive lobular carcinoma: A qualitative study from a prospective registry.
    2025 | UCSF Research Profile
  23. Reframing hormone-positive DCIS management: Effects of adjuvant therapies and surgical extent on any invasive recurrence.
    2025 | UCSF Research Profile
  24. Serum estradiol (sE2) levels in premenopausal (PreM) women receiving neoadjuvant ovarian function suppression (OFS) with the oral SERD amcenestrant, alone, or in combination with letrozole or abemaciclib in the I-SPY2 Endocrine Optimization Pilot (EOP).
    2025 | UCSF Research Profile
  25. Predicting nodal burden after neoadjuvant chemotherapy (NAC) with circulating tumor (ct)DNA for surgical planning: Results from the I-SPY2 trial.
    2025 | UCSF Research Profile
  26. A Multi-Institutional Analysis of Contralateral Axillary Metastases: Advanced Local-Regional Disease Divergent from Stage IV Breast Cancer.
    2025 | PubMed
  27. Positive Margin Rates After Breast-Conserving Surgery by Histologic Subtype: A Systematic Review and Meta-analysis Evaluating the Impact of Oncoplastic Surgery.
    2025 | PubMed
  28. Abstract 2367: Changes in breast hormone signaling and inflammation underlie radiologic features of cancer risk.
    2025 | UCSF Research Profile
  29. 410 Fine Needle Aspiration Biopsy of Breast Specimens Effectively Harvests Cells for Patient-Derived Organoids Modeling Breast Ductal Carcinoma In Situ.
    2025 | UCSF Research Profile
  30. Abstract No. 239 Cryoablation Versus Breast-Conserving Surgery for Early-Stage, Low-Risk Breast Cancer = 1.5 cm: A Cost-Effectiveness Analysis.
    2025 | UCSF Research Profile
  31. A pooled analysis evaluating prognostic significance of Residual Cancer Burden in invasive lobular breast cancer.
    2025 | PubMed
  32. Oncologic Outcomes with De-Escalation of Axillary Surgery After Neoadjuvant Chemotherapy for Breast Cancer: Results from > 1500 Patients on the I-SPY2 Clinical Trial.
    2025 | PubMed
  33. Tumor Morphology for Prediction of Poor Responses Early in Neoadjuvant Chemotherapy for Breast Cancer: A Multicenter Retrospective Study.
    2024 | PubMed
  34. Balancing risks of surgical complications and positive margins for patients with invasive lobular carcinoma of the breast and elevated BMI: An institutional cohort study.
    2024 | PubMed
  35. Regional lymph node changes on breast MRI in patients with early-stage breast cancer receiving neoadjuvant chemo-immunotherapy.
    2024 | PubMed
  36. Reply to: "Surgery of the primary tumor in patients with de novo metastatic breast cancer: a nationwide population-based retrospective cohort study in Belgium and the National Cancer Database (NCDB)".
    2024 | PubMed
  37. Variation in surgical treatment by body mass index in patients with invasive lobular carcinoma of the breast.
    2024 | PubMed
  38. Therapeutic response and outcomes with uncommon breast cancer subtypes in the I-SPY trial 2010-2022.
    2024 | UCSF Research Profile
  39. Change in Biomarker Profile After Neoadjuvant Chemotherapy is Prognostic and Common Among Patients with HER2+ Breast Cancer.
    2024 | PubMed
  40. Magnetic resonance imaging insights from active surveillance of women with ductal carcinoma in situ.
    2024 | PubMed
  41. ASO Author Reflections: Evolving Paradigms in Axillary Management for Breast Cancer: Insights from the ISPY-2 Neoadjuvant Chemotherapy Trial.
    2024 | PubMed
  42. ASO Author Reflections: Detecting Local Recurrence After Primary Treatment for Invasive Lobular Carcinoma of the Breast.
    2024 | PubMed
  43. International survey on invasive lobular breast cancer identifies priority research questions.
    2024 | PubMed
  44. Clipping the Positive Lymph Node in Patients with Clinically Node Positive Breast Cancer Treated with Neoadjuvant Chemotherapy: Impact on Axillary Surgery in the ISPY-2 Clinical Trial.
    2024 | PubMed
  45. Internal Mammary Lymphadenopathy Does Not Impact Oncologic Outcomes in Patients Treated with Neoadjuvant Chemotherapy: Results from the I-SPY2 Clinical Trial.
    2024 | PubMed
  46. Surveillance Strategies After Primary Treatment for Patients with Invasive Lobular Carcinoma of the Breast: Method of Local Recurrence Detection After Breast-Conserving Surgery.
    2024 | PubMed
  47. Elucidating the immune active state of HR+HER2- MammaPrint High 2 early breast cancer.
    2024 | UCSF Research Profile
  48. Impact of extent of disease at presentation on oncologic outcomes according to pathologic response to neoadjuvant systemic therapy among participants of the I-SPY2 clinical trial.
    2024 | UCSF Research Profile
  49. The neoadjuvant approach to treatment of breast cancer: Multidisciplinary management to improve outcomes.
    2024 | UCSF Research Profile
  50. Therapeutic response and outcomes with less common breast cancer subtypes in the I-SPY trial 2011-2022.
    2024 | UCSF Research Profile
  51. I-SPY2 Endocrine Optimization Pilot (EOP): Neoadjuvant amcenestrant +/- abemaciclib +/- letrozole in molecularly selected patients (pts) with HR+ HER2- stage 2/3 breast cancer (BC).
    2024 | UCSF Research Profile
  52. Invasive lobular breast cancer: Focus on prevention, genetics, diagnosis, and treatment.
    2024 | PubMed
  53. ASO Author Reflections: The Oncologic Safety of Immediate Oncoplastic Approaches in Invasive Lobular Carcinoma.
    2024 | PubMed
  54. Oncologic Safety of Immediate Oncoplastic Surgery Compared with Standard Breast-Conserving Surgery for Patients with Invasive Lobular Carcinoma.
    2024 | PubMed
  55. Abstract PO4-02-03: Distribution of MammaPrint, BluePrint, and Response Predictive Subtypes based on ImPrint and Reprint in ER+/HER2- Invasive Lobular Carcinoma – A FLEX sub study.
    2024 | UCSF Research Profile
  56. Abstract PO5-26-07: Surgery for Invasive Lobular Carcinoma: A Patient Experience Survey from the Lobular Breast Cancer Alliance.
    2024 | UCSF Research Profile
  57. Circulating tumor cells in early lobular versus ductal breast cancer and their associations with prognosis.
    2024 | PubMed
  58. Abstract A059: Heterogeneous cell populations in organoid models derived from breast preinvasive and invasive carcinomas after endocrine therapy.
    2024 | UCSF Research Profile
  59. Management of Concurrent Malignant Phyllodes Tumor and Invasive Breast Carcinoma.
    2024 | PubMed
  60. Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer risk.
    2024 | PubMed
  61. ASO Visual Abstract: Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes.
    2024 | PubMed
  62. Clinicopathologic and genetic analysis of invasive breast carcinomas in women with germline CHEK2 variants.
    2023 | PubMed
  63. ASO Visual Abstract: Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
    2023 | PubMed
  64. Tamoxifen or aromatase inhibitors with ovarian function suppression in pre-menopausal stage I-III lobular breast cancer.
    2023 | PubMed
  65. Letter to the Editor of Annals of Surgical Oncology concerning "Is Choosing Wisely Wise for Lobular Carcinoma in Patients over 70 Years of Age? A National Cancer Database Analysis of Sentinel Node Practice Patterns".
    2023 | PubMed
  66. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database (NCDB).
    2023 | PubMed
  67. 356P Prognostic value of the residual cancer burden after neoadjuvant chemotherapy for invasive lobular breast cancer: An international pooled cohort study.
    2023 | UCSF Research Profile
  68. Erratum: 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression - CORRIGENDUM.
    2023 | PubMed
  69. Nipple-Sparing Mastectomies in Patients over the Age of 60 Years: Factors Associated with Surgical Outcomes.
    2023 | PubMed
  70. ASO Author Reflections: Menopausal Status Does Not Predict Successful Breast Conservation Surgery After Neoadjuvant Chemotherapy in Invasive Lobular Carcinoma.
    2023 | PubMed
  71. Successful Breast Conservation After Neoadjuvant Chemotherapy in Lobular Breast Cancer: The Role of Menopausal Status in Response to Treatment.
    2023 | PubMed
  72. Area Deprivation Index in Patients with Invasive Lobular Carcinoma of the Breast: Associations with Tumor Characteristics and Outcomes.
    2023 | PubMed
  73. Quantifying hormone receptor status in lobular breast cancer in an institutional series: the relationship between estrogen and progesterone receptor status and outcomes.
    2023 | PubMed
  74. The impact of histologic subtype on primary site surgery in the management of metastatic lobular versus ductal breast cancer: a population based study from the National Cancer Database.
    2023 | PubMed
  75. Predictors of Early Versus Late Recurrence in Invasive Lobular Carcinoma of the Breast: Impact of Local and Systemic Therapy.
    2023 | PubMed
  76. ASO Author Reflections: Patient, Tumor, and Treatment Characteristics Predict Early Versus Late Recurrence in Patients with Invasive Lobular Carcinoma of the Breast.
    2023 | PubMed
  77. Editorial: Contrast mammography-a promising tool for the pre-operative evaluation of lobular breast cancer.
    2023 | PubMed
  78. Changes in Surgical Management of the Axilla Over 11 Years - Report on More Than 1500 Breast Cancer Patients Treated with Neoadjuvant Chemotherapy on the Prospective I-SPY2 Trial.
    2023 | PubMed
  79. Metabolic Positron Emission Tomography in Breast Cancer.
    2023 | PubMed
  80. Breast Conservation Surgery and Mastectomy Have Similar Locoregional Recurrence After Neoadjuvant Chemotherapy: Results From 1462 Patients on the Prospective, Randomized I-SPY2 Trial.
    2023 | PubMed
  81. Prognostic Significance of Residual Ductal Carcinoma In Situ After Complete Response of Invasive Breast Cancer to Neoadjuvant Therapy-Reply.
    2023 | PubMed
  82. Time to Surgery in Breast Cancer-Is Faster Always Better?
    2023 | PubMed
  83. 407 Moving from observational studies to a clinical trial: the impact of obesity and surgical weight loss on breast imaging, tissue, and cancer screening experience: the B-BRITE study.
    2023 | UCSF Research Profile
  84. 53 The development of a multi-institutional prospective registry for patients with metastatic invasive lobular carcinoma: identifying new markers of disease progression.
    2023 | UCSF Research Profile
  85. HER-2 low status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    2023 | PubMed
  86. Abstract HER2-14: HER2-14 HER-2 low status in early stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    2023 | UCSF Research Profile
  87. Abstract P2-03-16: Quantifying estrogen and progesterone receptor status in early-stage invasive lobular carcinoma of the breast: associated factors and outcomes in an institutional series.
    2023 | UCSF Research Profile
  88. Abstract P3-09-01: Characterization of residual disease after neoadjuvant selective estrogen receptor degrader (SERD) therapy using tumor organoids in the I-SPY Endocrine Optimization Protocol (EOP).
    2023 | UCSF Research Profile
  89. Abstract P6-05-10: An international survey on invasive lobular breast cancer (ILC) reveals gaps in knowledge and top priority research areas.
    2023 | UCSF Research Profile
  90. Abstract P6-08-09: Self-identified race and Area Deprivation Index in patients with invasive lobular carcinoma of the breast: associations with tumor characteristics and event free survival.
    2023 | UCSF Research Profile
  91. Triple-Negative Apocrine Carcinomas: Toward a Unified Group With Shared Molecular Features and Clinical Behavior.
    2023 | PubMed
  92. Expanding Candidacy for Nipple-sparing Mastectomy in Women with Large or Ptotic Breasts: Staged Reconstruction Outcomes.
    2023 | PubMed
  93. Identifying Good Candidates for Active Surveillance of Ductal Carcinoma In Situ: Insights from a Large Neoadjuvant Endocrine Therapy Cohort.
    2022 | PubMed
  94. Implementation, evaluation, and modification of a near-peer learning group in graduate surgical education.
    2022 | PubMed
  95. ASO Visual Abstract: The 21-Gene Recurrence Score in Clinically High Risk Lobular and Ductal Breast Cancer-A National Cancer Database Study.
    2022 | PubMed
  96. Association of Residual Ductal Carcinoma In Situ With Breast Cancer Recurrence in the Neoadjuvant I-SPY2 Trial.
    2022 | PubMed
  97. Hereditary vs Sporadic Invasive Lobular Carcinoma and Impact of Locoregional Therapy on Disease-Free Survival.
    2022 | UCSF Research Profile
  98. Molecular Imaging for Estrogen Receptor-Positive Breast Cancer: Clinical Applications of Whole Body and Dedicated Breast Positron Emission Tomography.
    2022 | PubMed
  99. See one, do one, teach one: a flipped classroom to make quality improvement experiential in surgical residency.
    2022 | UCSF Research Profile
  100. The 21-Gene Recurrence Score in Clinically High-Risk Lobular and Ductal Breast Cancer: A National Cancer Database Study.
    2022 | PubMed
  101. ASO Author Reflections: Discordant Clinical and Molecular Risk in Invasive Lobular Carcinoma of the Breast: The 21-Gene Recurrence Score in the National Cancer Database by Histologic Subtype.
    2022 | PubMed
  102. Abstract LB021: Mechanosensitive hormone signaling promotes mammary progenitor expansion and breast cancer progression.
    2022 | UCSF Research Profile
  103. Pathologic complete response (pCR) rates for HR+/HER2- breast cancer by molecular subtype in the I-SPY2 Trial.
    2022 | UCSF Research Profile
  104. Association of Residual Cancer Burden After Neoadjuvant Therapy and Event-Free Survival in Breast Cancer-Reply.
    2022 | PubMed
  105. Emotional Regulation in Surgery: Fostering Well-Being, Performance, and Leadership.
    2022 | PubMed
  106. Abstract OT1-10-02: I-SPY2 endocrine optimization protocol (EOP): A pilot neoadjuvant endocrine therapy study with amcenestrant as monotherapy or in combination with abemacicilib or letrozole in molecularly selected HR+/HER2- clinical stage 2/3 breast can
    2022 | UCSF Research Profile
  107. Abstract P2-02-02: Differences in levels of circulating tumor cells (CTC) and disseminated tumor cells (DTC) in early-stage lobular versus ductal breast cancer.
    2022 | UCSF Research Profile
  108. Abstract P3-02-01: Initial experience of FES-dedicated breast PET imaging of early-stage ER+ invasive lobular carcinoma.
    2022 | UCSF Research Profile
  109. Abstract P3-02-02: FES-dedicated breast PET uptake in early-stage ER+ breast cancers.
    2022 | UCSF Research Profile
  110. Abstract P3-03-07: Single-institution retrospective analysis of lymph node (LN) change on breast MRI in patients with high risk early-stage breast cancer receiving neoadjuvant chemotherapy with and without immunotherapy on the ISPY-2 TRIAL.
    2022 | UCSF Research Profile
  111. The incidence of discordant clinical and genomic risk in patients with invasive lobular or ductal carcinoma of the breast: a National Cancer Database Study.
    2021 | PubMed
  112. O13 BIOLOGIC VERSUS SYNTHETIC MESH IN VENTRAL HERNIA REPAIR: PARTICIPANT-LEVEL ANALYSIS OF TWO RANDOMIZED CONTROLLED TRIALS AT ONE YEAR.
    2021 | UCSF Research Profile
  113. Obesity and menopausal status impact the features and molecular phenotype of invasive lobular breast cancer.
    2021 | PubMed
  114. Decreased enrollment in breast cancer trials by histologic subtype: does invasive lobular carcinoma resist RECIST?
    2021 | PubMed
  115. Ganitumab and metformin plus standard neoadjuvant therapy in stage 2/3 breast cancer.
    2021 | PubMed
  116. Trigger point injection for post-mastectomy pain: a simple intervention with high rate of long-term relief.
    2021 | PubMed
  117. Correction to: Applications of 3D printing in breast cancer management.
    2021 | PubMed
  118. Positive margins after mastectomy in patients with invasive lobular carcinoma of the breast: Incidence and management strategies.
    2021 | PubMed
  119. Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.
    2021 | UCSF Research Profile
  120. Early onset, multiple, bilateral fibroadenomas of the breast: a case report.
    2021 | PubMed
  121. Invasive Lobular Carcinoma of the Breast: Ongoing Trials, Challenges, and Future Directions.
    2021 | UCSF Research Profile
  122. Preventing Recurrence in Clean and Contaminated Hernias Using Biologic Versus Synthetic Mesh in Ventral Hernia Repair: The PRICE Randomized Clinical Trial.
    2021 | PubMed
  123. Relationship between body mass index and malignancy rates of MRI-guided breast biopsies: impact of clinicodemographic factors.
    2021 | PubMed
  124. ASO Author Reflections: Changes in Primary Treatment Strategy for Invasive Lobular Carcinoma Highlight the Need for Better Predictors of Therapy Response.
    2021 | PubMed
  125. Changes in Management Strategy and Impact of Neoadjuvant Therapy on Extent of Surgery in Invasive Lobular Carcinoma of the Breast: Analysis of the National Cancer Database (NCDB).
    2021 | PubMed
  126. Accuracy of breast MRI in evaluating nodal status after neoadjuvant therapy in invasive lobular carcinoma.
    2021 | PubMed
  127. Abstract PD5-01: Magnetic resonance imaging insights from an active surveillance cohort of women with DCIS.
    2021 | UCSF Research Profile
  128. Abstract PD6-08: DCE-MRI derived imaging features for characterizing invasive lobular breast cancer and predicting recurrence-free survival after neoadjuvant therapy.
    2021 | UCSF Research Profile
  129. Abstract PS1-03: Active surveillance for DCIS: Clinical outcomes at 5.6 years mean follow-up.
    2021 | UCSF Research Profile
  130. Abstract PS17-05: Relationship between body mass index and tumor subtype by menopausal status: An analysis in women with lobular carcinoma of the breast.
    2021 | UCSF Research Profile
  131. Contralateral prophylactic mastectomy: A narrative review of the evidence and acceptability.
    2021 | PubMed
  132. Applications of 3D printing in breast cancer management.
    2021 | PubMed
  133. A world-wide survey on kidney transplantation practices in breast cancer survivors: The need for new management guidelines.
    2021 | PubMed
  134. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast: Factors associated with false negatives.
    2021 | PubMed
  135. Stiff stroma increases breast cancer risk by inducing the oncogene ZNF217.
    2020 | PubMed
  136. Oncological Outcomes of Total Skin-Sparing Mastectomy for Invasive Lobular Carcinoma of the Breast: A 20-Year Institutional Experience.
    2020 | PubMed
  137. 274 Poster Unintended bias in clinical trials: The prevalence of entry criteria that exclude patients with invasive lobular carcinoma from metastatic breast cancer trials.
    2020 | UCSF Research Profile
  138. Evaluating the impact of axillary dissection on recurrence-free survival by extent of nodal disease in invasive lobular carcinoma of the breast.
    2020 | PubMed
  139. Breast conservation therapy versus mastectomy in the surgical management of invasive lobular carcinoma measuring 4 cm or greater.
    2020 | PubMed
  140. Current Landscape of Breast Cancer Imaging and Potential Quantitative Imaging Markers of Response in ER-Positive Breast Cancers Treated with Neoadjuvant Therapy.
    2020 | PubMed
  141. 4314 The Impact of Axillary Surgery on Recurrence-Free Survival in Invasive Lobular Carcinoma (ILC) of the Breast.
    2020 | UCSF Research Profile
  142. Accuracy of sentinel lymph node biopsy in invasive lobular carcinoma of the breast.
    2020 | UCSF Research Profile
  143. Mitotic score and pleomorphic histology in invasive lobular carcinoma of the breast: impact on disease-free survival.
    2020 | PubMed
  144. Abstract OT3-09-01: Use of Oncotype DX DCIS for disease management in a prospective DCIS registry.
    2020 | UCSF Research Profile
  145. Abstract P3-08-16: The impact of residual ductal carcinoma in situ on breast cancer recurrence in the neoadjuvant I-SPY2 TRIAL.
    2020 | UCSF Research Profile
  146. Abstract P4-13-01: Trends in primary management of invasive lobular carcinoma: An analysis of the National Cancer Database (NCDB).
    2020 | UCSF Research Profile
  147. Abstract P5-08-05: Risk of subsequent events after initial diagnosis of ductal carcinoma in situ - A large multi-center registry study.
    2020 | UCSF Research Profile
  148. Abstract P6-16-06: Improved early stratification of invasive cancer risk using MRI in a ductal carcinoma in-situ short-term active surveillance cohort treated with neoadjuvant endocrine therapy.
    2020 | UCSF Research Profile
  149. Abstract PD9-08: Accuracy of ultrasound in evaluating response to neoadjuvant therapy in invasive lobular carcinoma of the breast.
    2020 | UCSF Research Profile
  150. Pragmatic Trials and Approaches to Transforming Care.
    2020 | UCSF Research Profile
  151. Abdominal Imaging of Pancreatic Cysts and Cyst-Associated Pancreatic Cancer in BRCA1/2 Mutation Carriers: A Retrospective Cross-Sectional Study.
    2019 | PubMed
  152. Success rates of re-excision after positive margins for invasive lobular carcinoma of the breast.
    2019 | PubMed
  153. Editorial: Applying Margin Consensus Guidelines to Invasive Lobular Carcinoma of the Breast.
    2019 | PubMed
  154. Feasibility of Magnetic Seeds for Preoperative Localization of Axillary Lymph Nodes in Breast Cancer Treatment.
    2019 | PubMed
  155. Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    2019 | PubMed
  156. Synchronous Breast Implant-associated Anaplastic Large Cell Lymphoma and Invasive Carcinoma: Genomic Profiling and Management Implications.
    2019 | PubMed
  157. Abstract 118: The Impact of Post-Operative Prophylactic Antibiotics in Immediate 2-Stage Prepectoral Breast Reconstruction.
    2019 | UCSF Research Profile
  158. Changes in mammographic density following bariatric surgery.
    2019 | PubMed
  159. Abstract P1-15-15: Accuracy of MRI after neoadjuvant therapy for invasive lobular carcinoma of the breast.
    2019 | UCSF Research Profile
  160. Abstract P4-11-01: A simple intervention for long-term relief of chronic post mastectomy pain.
    2019 | UCSF Research Profile
  161. Abstract P6-01-04: Initial experience of dedicated breast PET imaging of ER+ breast cancers using [F-18]fluoroestradiol.
    2019 | UCSF Research Profile
  162. Abstract PD7-06: Molecular subtypes of invasive lobular breast cancer in the I-SPY2 TRIAL.
    2019 | UCSF Research Profile
  163. Erratum: Author Correction: Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    2019 | PubMed
  164. Functional Status and Survival After Breast Cancer Surgery in Nursing Home Residents.
    2018 | PubMed
  165. ASO Author Reflections: Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    2018 | PubMed
  166. Surgical Standards for Management of the Axilla in Breast Cancer Clinical Trials with Pathological Complete Response Endpoint.
    2018 | PubMed
  167. Breast Conservation and Negative Margins in Invasive Lobular Carcinoma: The Impact of Oncoplastic Surgery and Shave Margins in 358 Patients.
    2018 | PubMed
  168. 452 (PB-085) The impact of mitotic score versus pleomorphic subtype on disease free survival in invasive lobular carcinoma of the breast.
    2018 | UCSF Research Profile
  169. Abstract P2-12-16: The use of oncoplastic surgical techniques to increase successful breast conservation in invasive lobular carcinoma of the breast.
    2018 | UCSF Research Profile
  170. Abstract P5-12-04: The impact of bariatric surgery on mammographic breast density.
    2018 | UCSF Research Profile
  171. Abstract P5-22-22: Breast tumor location in BRCA mutation carriers and implications for prevention.
    2018 | UCSF Research Profile
  172. Breast tumor location in BRCA mutation carriers and implications for prevention.
    2017 | UCSF Research Profile
  173. Characterizing the immune microenvironment in high-risk ductal carcinoma in situ of the breast.
    2016 | PubMed
  174. The Novel Application of Genomic Profiling Assays to Shorten Inactive Status for Potential Kidney Transplant Recipients With Breast Cancer.
    2016 | PubMed
  175. How to use magnetic resonance imaging following neoadjuvant chemotherapy in locally advanced breast cancer.
    2015 | PubMed
  176. Preventing Overdiagnosis and Overtreatment: Just the Next Step in the Evolution of Breast Cancer Care.
    2015 | PubMed
  177. Abstract PD1-5: Characterizing the Tumor Immune MicroEnvironment (TIME) in high-risk ductal carcinoma in situ.
    2015 | UCSF Research Profile
  178. Abstract 165: Suppressed immunity and macrophages characterize high risk high grade DCIS.
    2014 | UCSF Research Profile
  179. The prognostic implications of macrophages expressing proliferating cell nuclear antigen in breast cancer depend on immune context.
    2013 | PubMed
  180. Clinically meaningful tumor reduction rates vary by prechemotherapy MRI phenotype and tumor subtype in the I-SPY 1 TRIAL (CALGB 150007/150012; ACRIN 6657).
    2013 | PubMed
  181. Lobular histology and response to neoadjuvant chemotherapy in invasive breast cancer.
    2012 | PubMed
  182. Biology of breast cancer in Nigerian women: a pilot study.
    2012 | PubMed
  183. Elevated levels of proliferating and recently migrated tumor-associated macrophages confer increased aggressiveness and worse outcomes in breast cancer.
    2012 | PubMed
  184. P1-06-10: Lobular Breast Cancer and NAC: Combined Results from the NKI and I-SPY 1 Trial.
    2011 | UCSF Research Profile
  185. P4-09-19: PCNA+ Tumor Associated Macrophages Are Associated with M1 and M2 Gene Expression, and Confer Poor Prognosis in the Absence of Anti-Tumor Immune Environment.
    2011 | UCSF Research Profile
  186. PD02-05: MRI Phenotype and Tumor Subtype Affect Breast Conservation Eligibility and MRI Accuracy in the I-SPY 1 Trial.
    2011 | UCSF Research Profile
  187. Elevated PCNA+ tumor-associated macrophages in breast cancer are associated with early recurrence and non-Caucasian ethnicity.
    2011 | PubMed
  188. Identification of pathogenic macrophages in breast cancer as markers of tumor aggressiveness.
    2011 | UCSF Research Profile
  189. Benign Thoracic Disease in the Elderly.
    2011 | UCSF Research Profile
  190. Tumor-associated macrophages in breast cancer as potential biomarkers for new treatments and diagnostics.
    2011 | PubMed
  191. Abstract P2-09-11: Response of Invasive Lobular Cancers to Neoadjuvant Therapy.
    2010 | UCSF Research Profile
  192. Evaluation of levels of proliferating macrophages in patients at a county hospital and those with early recurrences.
    2010 | UCSF Research Profile
  193. Long-term survival and renal transplantation in a monozygotic twin with cloacal dysgenesis sequence.
    2009 | PubMed
  194. Bacteriologic features of surgical site infections following breast surgery.
    2009 | PubMed
  195. Benign thoracic disease in the elderly.
    2009 | PubMed
  196. Variation in annual volume at a university hospital does not predict mortality for pancreatic resections.
    2009 | PubMed
  197. Image of the month--quiz case. Traumatic intramuscular cyst of the duodenum.
    2005 | PubMed
  198. Quality-of-life issues in psoriasis.
    2004 | PubMed